Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART [highly active antiretroviral therapy] in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen

Trial Profile

Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART [highly active antiretroviral therapy] in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2009

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 Jun 2009 Results published in the Journal of Acquired Immune Deficiency Syndrome.
    • 09 Nov 2008 Results were presented at the 9th International Congress on Drug Therapy in HIV Infection.
    • 09 Nov 2008 Results were presented at the 9th International Congress on Drug Therapy in HIV Infection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top